{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T02:49:31Z","timestamp":1760237371023,"version":"build-2065373602"},"reference-count":33,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2020,5,11]],"date-time":"2020-05-11T00:00:00Z","timestamp":1589155200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003638","name":"Korea Health and Welfare Information Service","doi-asserted-by":"publisher","award":["HO15C0003"],"award-info":[{"award-number":["HO15C0003"]}],"id":[{"id":"10.13039\/501100003638","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Backgrounds: Radioimmunotherapy (RIT) serves as a targeted therapy for non-Hodgkin lymphomas (NHL). Although HIF(Hypoxia-inducible factors)-1\u03b1 is an important biomarker during radiation therapy, its role in NHL is unclear. Atorvastatin (ATV) is used as a combination drug for chemotherapy. Methods: We investigated whether ATV downregulated tumor radio-resistance and enhanced the anticancer effect of 131I-RTX (rituximab) in Raji xenograft mouse models. First, the increased uptake and enhanced therapeutic effect of 131I-RTX by ATV was confirmed using molecular imaging in Raji xenograft subcutaneous model and orthotropic model with SPECT and IVIS images. Second, we examined the profile of differentially expressed miRNAs using miRNA array. Results: We found that miR-346 inhibited HIF-1\u03b1\/VEGF (Vascular endothelial growth factor) during ATV combination therapy with 131I-RTX. The underlying mechanism of ATV involved induction of anti-angiogenesis and radiosensitivity by downregulating HIF-1\u03b1 in Raji cells. Conclusion: Our findings suggested that combination therapy with ATV and 131I-RTX is a promising strategy for enhancing the potency of 131I-RTX therapy in poorly responding patients and those with radio-resistance.<\/jats:p>","DOI":"10.3390\/cancers12051203","type":"journal-article","created":{"date-parts":[[2020,5,11]],"date-time":"2020-05-11T12:26:30Z","timestamp":1589199990000},"page":"1203","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Inhibition of HIF-1\u03b1 by Atorvastatin During 131I-RTX Therapy in Burkitt\u2019s Lymphoma Model"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6476-163X","authenticated-orcid":false,"given":"Eun-Ho","family":"Kim","sequence":"first","affiliation":[{"name":"Division of Radiation Biomedical Research, Korea Institute of Radiological and Medical Sciences, 75 Nowon-ro, Nowon-gu, Seoul 01812, Korea"},{"name":"Department of Biochemistry, School of Medicine, Catholic University of Daegu, 33, 17-gil, Duryugongwon-ro, Nam-gu, Daegu 705-718, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hae Young","family":"Ko","sequence":"additional","affiliation":[{"name":"Division of RI Application, Korea Institute of Radiological and Medical Sciences (KIRAMS), 75 Nowon-ro, Nowon-gu, Seoul 01812, Korea"},{"name":"Department of Nuclear Medicine, Yonsei University College of Medicine, Seoul 03722, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A Ram","family":"Yu","sequence":"additional","affiliation":[{"name":"Laboratory Animal Center, Osong Medical Innovation Foundation, Osong, Chungbuk 28159, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6990-3900","authenticated-orcid":false,"given":"Hyeongi","family":"Kim","sequence":"additional","affiliation":[{"name":"Division of RI Application, Korea Institute of Radiological and Medical Sciences (KIRAMS), 75 Nowon-ro, Nowon-gu, Seoul 01812, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javeria","family":"Zaheer","sequence":"additional","affiliation":[{"name":"Division of RI Application, Korea Institute of Radiological and Medical Sciences (KIRAMS), 75 Nowon-ro, Nowon-gu, Seoul 01812, Korea"},{"name":"Radiologcial and Medico-Oncological Sciences, University of science and technology (UST), Seoul 01812, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyun Ji","family":"Kang","sequence":"additional","affiliation":[{"name":"Division of RI Application, Korea Institute of Radiological and Medical Sciences (KIRAMS), 75 Nowon-ro, Nowon-gu, Seoul 01812, Korea"},{"name":"Radiologcial and Medico-Oncological Sciences, University of science and technology (UST), Seoul 01812, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Young-Cheol","family":"Lim","sequence":"additional","affiliation":[{"name":"Division of RI Application, Korea Institute of Radiological and Medical Sciences (KIRAMS), 75 Nowon-ro, Nowon-gu, Seoul 01812, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyung Deuk","family":"Cho","sequence":"additional","affiliation":[{"name":"Division of RI Application, Korea Institute of Radiological and Medical Sciences (KIRAMS), 75 Nowon-ro, Nowon-gu, Seoul 01812, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyun-Yoo","family":"Joo","sequence":"additional","affiliation":[{"name":"Division of Radiation Biomedical Research, Korea Institute of Radiological and Medical Sciences, 75 Nowon-ro, Nowon-gu, Seoul 01812, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min Kyoung","family":"Kang","sequence":"additional","affiliation":[{"name":"Laboratory Animal Center, Osong Medical Innovation Foundation, Osong, Chungbuk 28159, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jae Jun","family":"Lee","sequence":"additional","affiliation":[{"name":"Laboratory Animal Center, Osong Medical Innovation Foundation, Osong, Chungbuk 28159, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seung-Sook","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Pathology, Korea Cancer Center Hospital, Korea Institute of Radiological and Medical Sciences, Seoul 01812, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hye Jin","family":"Kang","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Department of Internal Medicine, Korea Cancer Center Hospital, Korea Institute of Radiological and Medical Sciences, Seoul 01812, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sang Moo","family":"Lim","sequence":"additional","affiliation":[{"name":"Division of RI Application, Korea Institute of Radiological and Medical Sciences (KIRAMS), 75 Nowon-ro, Nowon-gu, Seoul 01812, Korea"},{"name":"Department of Nuclear Medicine, Korea Cancer Center Hospital, Korea Institute of Radiological and Medical Sciences, Seoul 01812, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8965-9538","authenticated-orcid":false,"given":"Jin Su","family":"Kim","sequence":"additional","affiliation":[{"name":"Division of RI Application, Korea Institute of Radiological and Medical Sciences (KIRAMS), 75 Nowon-ro, Nowon-gu, Seoul 01812, Korea"},{"name":"Radiologcial and Medico-Oncological Sciences, University of science and technology (UST), Seoul 01812, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2020,5,11]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/j.ijrobp.2004.02.065","article-title":"Radiobiology of radioimmunotherapy: Targeting CD20 B-cell antigen in non-Hodgkin\u2019s lymphoma","volume":"59","author":"Hernandez","year":"2004","journal-title":"Int. J Radiat. Oncol. Biol. Phys."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1182\/blood.V83.2.435.435","article-title":"Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20","volume":"83","author":"Reff","year":"1994","journal-title":"Blood"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1093\/annonc\/mdg175","article-title":"An overview of the current clinical use of the anti-CD20 monoclonal antibody rituximab","volume":"14","author":"Boye","year":"2003","journal-title":"Ann. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"803","DOI":"10.2165\/00003495-200363080-00005","article-title":"Rituximab: A review of its use in non-Hodgkin\u2019s lymphoma and chronic lymphocytic leukaemia","volume":"63","author":"Plosker","year":"2003","journal-title":"Drugs"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"157","DOI":"10.3121\/cmr.3.3.157","article-title":"Radioimmunotherapy for Non-Hodgkin\u2019s Lymphoma","volume":"3","author":"Rao","year":"2005","journal-title":"Clin. Med. Res."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"4418","DOI":"10.1200\/JCO.2005.05.3470","article-title":"Multicenter phase II clinical study of 131I--rituximab radioimmunotherapy in relapsed or refractory indolent non-Hodgkin\u2019s lymphoma","volume":"24","author":"Leahy","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1615\/JEnvironPatholToxicolOncol.2013006843","article-title":"Cellular internalization and mechanism of cytotoxicity of 131I-rituximab in Raji cells","volume":"32","author":"Kumar","year":"2013","journal-title":"J. Environ. Pathol. Toxicol. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.ijrobp.2006.05.030","article-title":"Radioimmunotherapy for non-Hodgkin\u2019s lymphoma: A review for radiation oncologists","volume":"66","author":"Macklis","year":"2006","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1007\/s00280-013-2087-z","article-title":"Repeated radioimmunotherapy with 131I-rituximab for patients with low-grade and aggressive relapsed or refractory B cell non-Hodgkin lymphoma","volume":"71","author":"Kang","year":"2013","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1080\/17474086.2017.1318053","article-title":"Lymphoma classification update: B-cell non-Hodgkin lymphomas","volume":"10","author":"Jiang","year":"2017","journal-title":"Expert Rev. Hematol."},{"key":"ref_11","first-page":"k3204","article-title":"Non-Hodgkin lymphoma","volume":"362","author":"Ajithkumar","year":"2018","journal-title":"BMJ"},{"key":"ref_12","first-page":"6","article-title":"Treating Burkitt Lymphoma in Adults","volume":"10","author":"Casulo","year":"2016","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0140-6736(12)60605-9","article-title":"Non-Hodgkin lymphoma","volume":"380","author":"Shankland","year":"2012","journal-title":"Lancet"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1200\/JCO.2009.24.1893","article-title":"Hypoxia-inducible factor-1 {alpha} expression predicts superior survival in patients with diffuse large B-cell lymphoma treated with R-CHOP","volume":"28","author":"Evens","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Scandinavian Simvastatin Survival Study Group (1994). Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet, 344, 1383\u20131389.","DOI":"10.1016\/S0140-6736(94)90566-5"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1056\/NEJM199511163332001","article-title":"Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group","volume":"333","author":"Shepherd","year":"1995","journal-title":"N. Engl. J. Med."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Lee, S., Lee, H.J., Kang, H., Kim, E.H., Lim, Y.C., Park, H., Lim, S.M., Lee, Y.J., Kim, J.M., and Kim, J.S. (2019). Trastuzumab Induced Chemobrain, Atorvastatin Rescued Chemobrain with Enhanced Anticancer Effect and without Hair Loss-Side Effect. J. Clin. Med., 8.","DOI":"10.3390\/jcm8020234"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"D746","DOI":"10.1093\/nar\/gkv1045","article-title":"Expression Atlas update\u2014An integrated database of gene and protein expression in humans, animals and plants","volume":"44","author":"Petryszak","year":"2016","journal-title":"Nucleic Acids Res."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1136\/jcp.50.10.801","article-title":"A scoring system for immunohistochemical staining: Consensus report of the task force for basic research of the EORTC-GCCG. European Organization for Research and Treatment of Cancer-Gynaecological Cancer Cooperative Group","volume":"50","author":"Berns","year":"1997","journal-title":"J. Clin. Pathol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"e518","DOI":"10.1038\/cddis.2013.44","article-title":"HMG-CoA reductase inhibitors induce apoptosis of lymphoma cells by promoting ROS generation and regulating Akt, Erk and p38 signals via suppression of mevalonate pathway","volume":"4","author":"Qi","year":"2013","journal-title":"Cell Death. Dis."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.bbrc.2016.01.014","article-title":"miR-1182 inhibits growth and mediates the chemosensitivity of bladder cancer by targeting hTERT","volume":"470","author":"Zhou","year":"2016","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Othman, N., In, L.L., Harikrishna, J.A., and Hasima, N. (2013). Bcl-xL silencing induces alterations in hsa-miR-608 expression and subsequent cell death in A549 and SK-LU1 human lung adenocarcinoma cells. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0081735"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"3795","DOI":"10.1158\/0008-5472.CAN-07-6193","article-title":"Cancer cell death enhances the penetration and efficacy of oncolytic herpes simplex virus in tumors","volume":"68","author":"Nagano","year":"2008","journal-title":"Cancer Res."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1007\/s11307-012-0552-4","article-title":"Tumor dosimetry using 124I m-iodobenzylguanidine microPET\/CT for 131Im-iodobenzylguanidine treatment of neuroblastoma in a murine xenograft model","volume":"14","author":"Seo","year":"2012","journal-title":"Mol. Imaging Biol."},{"key":"ref_25","unstructured":"Bailey, D.L., Humm, J.L., Todd-Pokropek, A., and Aswegen, A.V. (2014). Nuclear. Medicine. Physics: A Handbook for. Teachers and. Students, IAEA."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1200\/JCO.2005.06.081","article-title":"Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis","volume":"23","author":"Hicklin","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"ref_27","unstructured":"Hall, E.J. (1997). Radiobiology for the Radiologist, J.B.Lippincott Co."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s13139-019-00598-7","article-title":"Measurement of Tumor Pressure and Strategies of Imaging Tumor Pressure for Radioimmunotherapy","volume":"53","author":"Kim","year":"2019","journal-title":"Nucl. Med. Mol. Imaging"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.nucmedbio.2011.10.020","article-title":"Combined-modality radioimmunotherapy: Synergistic effect of paclitaxel and additive effect of bevacizumab","volume":"39","author":"Jang","year":"2012","journal-title":"Nucl. Med. Biol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.jconrel.2012.06.025","article-title":"Pulsed high intensity focused ultrasound increases penetration and therapeutic efficacy of monoclonal antibodies in murine xenograft tumors","volume":"162","author":"Wang","year":"2012","journal-title":"J. Control Release"},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Zaheer, J., Kim, H., Lee, Y.J., Kim, J.S., and Lim, S.M. (2019). Combination Radioimmunotherapy Strategies for Solid Tumors. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20225579"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1007\/s13139-015-0392-7","article-title":"Combination Radioimmunotherapy Approaches and Quantification of Immuno-PET","volume":"50","author":"Kim","year":"2016","journal-title":"Nucl. Med. Mol. Imaging"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.molcel.2010.09.022","article-title":"Hypoxia-Inducible Factors and the Response to Hypoxic Stress","volume":"40","author":"Majmundar","year":"2010","journal-title":"Mol. Cell"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/12\/5\/1203\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T09:27:32Z","timestamp":1760174852000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/12\/5\/1203"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,11]]},"references-count":33,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2020,5]]}},"alternative-id":["cancers12051203"],"URL":"https:\/\/doi.org\/10.3390\/cancers12051203","relation":{},"ISSN":["2072-6694"],"issn-type":[{"type":"electronic","value":"2072-6694"}],"subject":[],"published":{"date-parts":[[2020,5,11]]}}}